A larger diameter of the main pulmonary artery predicts poorer outcomes in pulmonary arterial hypertension (PAH) patients, a study found.
Study objectives: Prior to the availability of the oral endothelin antagonist bosentan, most patients with pulmonary arterial hypertension (PAH) were treated with continuously infused ...